Bryan Johnson· Author
To try and continually improve dosing, we've extensively measured my sirolimus blood levels at various time points post administration.
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
To try and continually improve dosing, we've extensively measured my sirolimus blood levels at various time points post administration.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
Blood sirolimus levels post 13 mg: 90 min: 26.5 ng/mL 3.1 days: 3.6 ng/mL 4.1 days: 2.5 ng/mL 13 days: not detected
To continue our experimentation, this week I'll be changing to 13 mg and 9 mg.
13 days: not detected
Every two weeks, I take 13 mg of gastro protected Rapamune (Rx required).
Previously maintained a weekly Rapamycin dosing protocol of 6mg. 24 hours post blood Rapamycin levels of the 6 mg dose were 3.2 ng/mL.
4.1 days: 2.5 ng/mL
we've measured my Rapamycin blood levels 90 min, 4.1 days and 13 days post administration.
90 min: 26.5 ng/mL
To personalize dose and measure for safety and efficacy, we've measured my Rapamycin blood levels 90 min, 4.1 days and 13 days post administration.
once every two weeks Measured Rapamycin levels (via blood), 90 min post 13mg bi-weekly dose.
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.